Research breakthroughs. Policy shifts. Market moves.
Education & events. Delivered to your inbox every weekday.
Join 2,000+ clinicians, researchers & investors. Unsubscribe anytime.
Clinical trials, peer-reviewed studies, and breakthrough findings — distilled into what actually matters.
FDA, EMA, TGA decisions. State legislation. International regulatory shifts you need to know.
Funding rounds, acquisitions, clinic expansions. The commercial landscape at a glance.
Training programs, certification courses, and clinical skills development. From clinicians to researchers.
Upcoming conferences, workshops, and summits in psychedelic medicine. Don't miss key industry gatherings.
5-7 stories daily
Research, policy, business, education & events across the psychedelic landscape
Under 3 minutes
Every weekday at 7am
Global coverage
US, Europe, Australia & beyond
Compass Pathways' COMP360 moves closer to approval. Decision expected Q3 2026.
New JAMA Psychiatry study (n=1,247)...
14 service centers approved in...
That's your trip. See you tomorrow.
Yes. The Brief Trip is free. We may introduce premium features later, but the daily briefing will always be free.
Weekdays only. One email per day, every morning. No spam, ever.
A team tracking psychedelic medicine full-time. We read everything so you don't have to.
One click, any time. No hard feelings.
Your daily psychedelic briefing. 3 minutes. Every weekday.
Unsubscribe anytime. Your email stays private.